Kumi Mesaki1, Masaomi Yamane2, Seiichiro Sugimoto1, Masayoshi Fujisawa3, Teizo Yoshimura3, Takeshi Kurosaki4, Shinji Otani4, Shinichiro Miyoshi1, Takahiro Oto4, Akihiro Matsukawa3, Shinichi Toyooka1. 1. Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1, Shikata-cho, Kita-ku, Okayama, Okayama, 700-8558, Japan. 2. Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1, Shikata-cho, Kita-ku, Okayama, Okayama, 700-8558, Japan. yamane-m@cc.okayama-u.ac.jp. 3. Department of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. 4. Organ Transplant Center, Okayama University Hospital, Okayama, Japan.
Abstract
PURPOSE: Suppressor of cytokine signaling-3 (SOCS3) is a negative feedback inhibitor of cytokine signaling with T-cell-mediated immunosuppressive effects on obliterative bronchiolitis (OB). In this study, we aimed to investigate the impact of T-cell-specific overexpression of SOCS3 using a murine heterotopic tracheal transplantation (HTT) model. METHODS: Tracheal allografts from BALB/c mice were subcutaneously transplanted into wild-type C57BL/6J (B6; WT) mice and SOCS3 transgenic B6 (SOCS3TG) mice. Tracheal allografts were analyzed by immunohistochemistry and quantitative polymerase chain reaction assays at days 7 and 21. RESULTS: At day 21, allografts in SOCS3TG mice showed significant amelioration of airway obstruction and epithelial loss compared with allografts in WT mice. The intragraft expression of IFN-γ and CXCL10 was suppressed, while that of IL-4 was enhanced in SOCS3TG mice at day 7. The T-bet levels were lower in SOCS3TG allografts than in WT allografts at day 7. CONCLUSION: We revealed that the overexpression of SOCS3 in T cells effectively ameliorates OB development in a murine HTT model by inhibiting the Th1 phenotype in the early phase. Our results suggest that the regulation of the T-cell response, through the modulation of SOCS expression, has potential as a new therapeutic strategy for chronic lung allograft dysfunction.
PURPOSE:Suppressor of cytokine signaling-3 (SOCS3) is a negative feedback inhibitor of cytokine signaling with T-cell-mediated immunosuppressive effects on obliterative bronchiolitis (OB). In this study, we aimed to investigate the impact of T-cell-specific overexpression of SOCS3 using a murine heterotopic tracheal transplantation (HTT) model. METHODS: Tracheal allografts from BALB/c mice were subcutaneously transplanted into wild-type C57BL/6J (B6; WT) mice and SOCS3 transgenic B6 (SOCS3TG) mice. Tracheal allografts were analyzed by immunohistochemistry and quantitative polymerase chain reaction assays at days 7 and 21. RESULTS: At day 21, allografts in SOCS3TG mice showed significant amelioration of airway obstruction and epithelial loss compared with allografts in WT mice. The intragraft expression of IFN-γ and CXCL10 was suppressed, while that of IL-4 was enhanced in SOCS3TG mice at day 7. The T-bet levels were lower in SOCS3TG allografts than in WT allografts at day 7. CONCLUSION: We revealed that the overexpression of SOCS3 in T cells effectively ameliorates OB development in a murine HTT model by inhibiting the Th1 phenotype in the early phase. Our results suggest that the regulation of the T-cell response, through the modulation of SOCS expression, has potential as a new therapeutic strategy for chronic lung allograft dysfunction.
Authors: Yunge Zhao; Jacob R Gillen; Akshaya K Meher; Jordan A Burns; Irving L Kron; Christine L Lau Journal: J Thorac Cardiovasc Surg Date: 2015-09-07 Impact factor: 5.209
Authors: I P Neuringer; R B Mannon; T M Coffman; M Parsons; K Burns; J R Yankaskas; R M Aris Journal: Am J Respir Cell Mol Biol Date: 1998-09 Impact factor: 6.914
Authors: D C Neujahr; S D Perez; A Mohammed; O Ulukpo; E C Lawrence; F Fernandez; A Pickens; S D Force; M Song; C P Larsen; A D Kirk Journal: Am J Transplant Date: 2011-12-07 Impact factor: 8.086
Authors: S Samuel Weigt; Ariss DerHovanessian; W Dean Wallace; Joseph P Lynch; John A Belperio Journal: Semin Respir Crit Care Med Date: 2013-07-02 Impact factor: 3.119
Authors: Hongwei Qin; Lanfang Wang; Ting Feng; Charles O Elson; Sandrine A Niyongere; Sun Jung Lee; Stephanie L Reynolds; Casey T Weaver; Kevin Roarty; Rosa Serra; Etty N Benveniste; Yingzi Cong Journal: J Immunol Date: 2009-06-17 Impact factor: 5.422
Authors: Brice W McKane; Felix Fernandez; Kishore Narayanan; Shawn Marshbank; Solomon B Margolin; Martin Jendrisak; T Mohanakumar Journal: Transplantation Date: 2004-03-15 Impact factor: 4.939
Authors: S G Rønn; A Börjesson; C Bruun; P E Heding; H Frobøse; T Mandrup-Poulsen; A E Karlsen; J Rasschaert; S Sandler; N Billestrup Journal: Diabetologia Date: 2008-07-22 Impact factor: 10.122
Authors: Philippe H Lemaître; Benoît Vokaer; Louis-Marie Charbonnier; Yoichiro Iwakura; Marc Estenne; Michel Goldman; Oberdan Leo; Myriam Remmelink; Alain Le Moine Journal: PLoS One Date: 2013-07-30 Impact factor: 3.240